APO RESEARCH · REPORT
Inhaled Nitric Oxide
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Product & engineering
Understand the product.
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Selected research
Market Outlook & Growth Opportunities
Global Inhaled Nitric Oxide Market Outlook and Growth Opportunities 2026
Market perspective
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
Read the full market overview
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
This report provides an overview of the global Inhaled Nitric Oxide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Inhaled Nitric Oxide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Inhaled Nitric Oxide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inhaled Nitric Oxide market size, projected growth trends, production technologies, key applications, and end-use industries.
Inhaled Nitric Oxide Segment by Company
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
Inhaled Nitric Oxide Segment by Type
800 ppm
100 ppm
Others
Inhaled Nitric Oxide Segment by Application
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
Inhaled Nitric Oxide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Inhaled Nitric Oxide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Inhaled Nitric Oxide market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Inhaled Nitric Oxide significant trends, drivers, influence factors in global and regions.
6. To analyze Inhaled Nitric Oxide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhaled Nitric Oxide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhaled Nitric Oxide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhaled Nitric Oxide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Inhaled Nitric Oxide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inhaled Nitric Oxide industry.
Chapter 3: Detailed analysis of Inhaled Nitric Oxide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Inhaled Nitric Oxide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Inhaled Nitric Oxide in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- 800 ppm
- 100 ppm
- Others
Applications
- Near-term and Pre-term Infants PPHN
- Children and Adult ARDS
- Other Diseases
Companies covered
- Mallinckrodt
- Praxair (Linde plc)
- Air Liquide
- BOC Healthcare (Linde Group)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Inhaled Nitric Oxide Sales Value (2021-2032)
- 1.2.2 Global Inhaled Nitric Oxide Sales Volume (2021-2032)
- 1.2.3 Global Inhaled Nitric Oxide Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Inhaled Nitric Oxide Market Dynamics
- 2.1 Inhaled Nitric Oxide Industry Trends
- 2.2 Inhaled Nitric Oxide Industry Drivers
- 2.3 Inhaled Nitric Oxide Industry Opportunities and Challenges
- 2.4 Inhaled Nitric Oxide Industry Restraints
3 Inhaled Nitric Oxide Market by Company
- 3.1 Global Inhaled Nitric Oxide Company Revenue Ranking in 2025
- 3.2 Global Inhaled Nitric Oxide Revenue by Company (2021-2026)
- 3.3 Global Inhaled Nitric Oxide Sales Volume by Company (2021-2026)
- 3.4 Global Inhaled Nitric Oxide Average Price by Company (2021-2026)
- 3.5 Global Inhaled Nitric Oxide Company Ranking (2024-2026)
- 3.6 Global Inhaled Nitric Oxide Company Manufacturing Base and Headquarters
- 3.7 Global Inhaled Nitric Oxide Company Product Type and Application
- 3.8 Global Inhaled Nitric Oxide Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Inhaled Nitric Oxide Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Inhaled Nitric Oxide Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Inhaled Nitric Oxide Market by Type
- 4.1 Inhaled Nitric Oxide Type Introduction
- 4.1.1 800 ppm
- 4.1.2 100 ppm
- 4.1.3 Others
- 4.2 Global Inhaled Nitric Oxide Sales Volume by Type
- 4.2.1 Global Inhaled Nitric Oxide Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Inhaled Nitric Oxide Sales Volume by Type (2021-2032)
- 4.2.3 Global Inhaled Nitric Oxide Sales Volume Share by Type (2021-2032)
- 4.3 Global Inhaled Nitric Oxide Sales Value by Type
- 4.3.1 Global Inhaled Nitric Oxide Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Inhaled Nitric Oxide Sales Value by Type (2021-2032)
- 4.3.3 Global Inhaled Nitric Oxide Sales Value Share by Type (2021-2032)
5 Inhaled Nitric Oxide Market by Application
- 5.1 Inhaled Nitric Oxide Application Introduction
- 5.1.1 Near-term and Pre-term Infants PPHN
- 5.1.2 Children and Adult ARDS
- 5.1.3 Other Diseases
- 5.2 Global Inhaled Nitric Oxide Sales Volume by Application
- 5.2.1 Global Inhaled Nitric Oxide Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Inhaled Nitric Oxide Sales Volume by Application (2021-2032)
- 5.2.3 Global Inhaled Nitric Oxide Sales Volume Share by Application (2021-2032)
- 5.3 Global Inhaled Nitric Oxide Sales Value by Application
- 5.3.1 Global Inhaled Nitric Oxide Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Inhaled Nitric Oxide Sales Value by Application (2021-2032)
- 5.3.3 Global Inhaled Nitric Oxide Sales Value Share by Application (2021-2032)
6 Inhaled Nitric Oxide Regional Sales and Value Analysis
- 6.1 Global Inhaled Nitric Oxide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Inhaled Nitric Oxide Sales by Region (2021-2032)
- 6.2.1 Global Inhaled Nitric Oxide Sales by Region: 2021-2026
- 6.2.2 Global Inhaled Nitric Oxide Sales by Region (2027-2032)
- 6.3 Global Inhaled Nitric Oxide Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Inhaled Nitric Oxide Sales Value by Region (2021-2032)
- 6.4.1 Global Inhaled Nitric Oxide Sales Value by Region: 2021-2026
- 6.4.2 Global Inhaled Nitric Oxide Sales Value by Region (2027-2032)
- 6.5 Global Inhaled Nitric Oxide Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Inhaled Nitric Oxide Sales Value (2021-2032)
- 6.6.2 North America Inhaled Nitric Oxide Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Inhaled Nitric Oxide Sales Value (2021-2032)
- 6.7.2 Europe Inhaled Nitric Oxide Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Inhaled Nitric Oxide Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Inhaled Nitric Oxide Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Inhaled Nitric Oxide Sales Value (2021-2032)
- 6.9.2 South America Inhaled Nitric Oxide Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Inhaled Nitric Oxide Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Inhaled Nitric Oxide Sales Value Share by Country, 2025 VS 2032
7 Inhaled Nitric Oxide Country-level Sales and Value Analysis
- 7.1 Global Inhaled Nitric Oxide Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Inhaled Nitric Oxide Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Inhaled Nitric Oxide Sales by Country (2021-2032)
- 7.3.1 Global Inhaled Nitric Oxide Sales by Country (2021-2026)
- 7.3.2 Global Inhaled Nitric Oxide Sales by Country (2027-2032)
- 7.4 Global Inhaled Nitric Oxide Sales Value by Country (2021-2032)
- 7.4.1 Global Inhaled Nitric Oxide Sales Value by Country (2021-2026)
- 7.4.2 Global Inhaled Nitric Oxide Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.9.2 France Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.16.2 China Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.19.2 India Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Inhaled Nitric Oxide Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Inhaled Nitric Oxide Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Inhaled Nitric Oxide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Mallinckrodt
- 8.1.1 Mallinckrodt Company Information
- 8.1.2 Mallinckrodt Business Overview
- 8.1.3 Mallinckrodt Inhaled Nitric Oxide Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Mallinckrodt Inhaled Nitric Oxide Product Portfolio
- 8.1.5 Mallinckrodt Recent Developments
- 8.2 Praxair (Linde plc)
- 8.2.1 Praxair (Linde plc) Company Information
- 8.2.2 Praxair (Linde plc) Business Overview
- 8.2.3 Praxair (Linde plc) Inhaled Nitric Oxide Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Praxair (Linde plc) Inhaled Nitric Oxide Product Portfolio
- 8.2.5 Praxair (Linde plc) Recent Developments
- 8.3 Air Liquide
- 8.3.1 Air Liquide Company Information
- 8.3.2 Air Liquide Business Overview
- 8.3.3 Air Liquide Inhaled Nitric Oxide Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Air Liquide Inhaled Nitric Oxide Product Portfolio
- 8.3.5 Air Liquide Recent Developments
- 8.4 BOC Healthcare (Linde Group)
- 8.4.1 BOC Healthcare (Linde Group) Company Information
- 8.4.2 BOC Healthcare (Linde Group) Business Overview
- 8.4.3 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Sales, Value and Gross Margin (2021-2026)
- 8.4.4 BOC Healthcare (Linde Group) Inhaled Nitric Oxide Product Portfolio
- 8.4.5 BOC Healthcare (Linde Group) Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Inhaled Nitric Oxide Value Chain Analysis
- 9.1.1 Inhaled Nitric Oxide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Inhaled Nitric Oxide Sales Mode & Process
- 9.2 Inhaled Nitric Oxide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Inhaled Nitric Oxide Distributors
- 9.2.3 Inhaled Nitric Oxide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst